Bavarian Nordic Issues Warrants to Newly Appointed Member of the Executive ManagementHomeMailNewsFinanceSportsEntertainmentSearchMobileMoreYahooSearchNo matching results for ''Tip: Try a valid symbol or a specific company name for relevant resultsSign inMailFinance HomeWatchlistsMy PortfolioScreenersPremiumMarketsIndustriesPersonal FinanceVideosNewsTechU.S. Markets closedS&P 5002,978.76-137.63(-4.42%)Dow 3025,766.64-1,190.95(-4.42%)Nasdaq8,566.48-414.29(-4.61%)Bavarian Nordic Issues Warrants to Newly Appointed Member of the Executive ManagementGlobeNewswireJanuary 6, 2020ReblogShareTweetShareCOPENHAGEN, Denmark, January 6, 2020 – Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) today announced that the Board of Directors in Bavarian Nordic A/S has decided to issue warrants to Jean-Christophe May, newly appointed Chief Commercial Officer and member of the executive management. The decision is made in accordance with the shareholder authorization for the board of directors adopted as Article 5b of the Articles of Association and the Company’s guidelines regarding incentive remuneration.The Board of Directors has issued 23,763 warrants which entitle the warrant holder to subscribe for up to 23,763 shares in total with a nominal value of DKK 10 each at an exercise price of DKK 197 per share. The warrants may be exercised wholly or partly during eight fixed subscription periods during 2023 and 2024.The value of each warrant equals DKK 52.5 and is calculated on the Black-Scholes model with a risk-free interest rate of -0.65 per cent and on the historical volatility of the shares. The calculation is based on a share price of DKK 171.2.About Bavarian NordicBavarian Nordic is a fully integrated biotechnology company focused on the development, manufacture and commercialization of life-saving vaccines. We are a global leader in smallpox vaccines and has been a long-term supplier to the U.S. Strategic National Stockpile of a non-replicating smallpox vaccine, which has been approved by the FDA, also for the protection against monkeypox. Our commercial product portfolio furthermore contains market-leading vaccines against rabies and tick-borne encephalitis. Using our live virus vaccine platform technology, MVA-BN®, we have created a diverse portfolio of proprietary and partnered product candidates designed to save and improve lives by unlocking the power of the immune system, including an investigational Ebola vaccine, licensed to Janssen. For more information visit www.bavarian-nordic.com.Forward-looking statements This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of our control, that could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning our plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.ContactsRolf Sass SørensenVice President Investor Relations (EU)Tel: +45 61 77 47 43Graham Morrell, Paddock Circle Advisors (US)                 graham@paddockcircle.comTel: +1 781 686 9600Company Announcement no. 01 / 2020Attachment 2020-01-en ReblogShareTweetShareRecently ViewedYour list is empty.What to Read NextNXP Semiconductors CEO joins board of HPAmerican City Business JournalsPinterest adds DoorDash exec and Caviar lead Gokul Rajaram to its boardTechCrunchFormer Enterprise Bank CEO Peter Benoist diesAmerican City Business JournalsDoorDash Quietly Added Woman to All-Male Board Ahead of IPOBloombergHow Two Ten’s New CEO Plans to Boost Fundraising & Attract More Industry InsidersFootwear NewsRichard Branson’s Wealth Falls to Earth as Virgin Galactic SputtersBloombergA drug shortage due to the coronavirus is a 'considerable risk:' Fmr. FDA deputy commissionerYahoo Finance VideoBiocontainment expert on coronavirus: There's no need for average people to panic yetYahoo FinanceAmid coronavirus, bitcoin has fallen 6% this week to below $8,800Yahoo FinanceEl-Erian: The Fed will cut rates in March, if not beforeYahoo Finance VideoStock market live updates: Dow drops 1190 points amid coronavirus fears, S&P 500 sees fastest correction in historyYahoo FinanceMost face masks won’t protect you from the coronavirusYahoo FinanceDon’t buy the stock dip yet, says Goldman as it warns coronavirus will wipe out earnings growth this yearMarketWatchCoronavirus-induced stock selloff means IPO market is 'on holiday': veteran IPO analystYahoo FinanceMarket Watcher: Over six months we will see the markets higher Yahoo Finance VideoStock market live updates: Stock futures climb after historic rout; coronavirus fears persistYahoo Finance